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ABSTRACT
Deregulation of mTOR and IGF pathways is frequent in hepatocellular carcinoma 
(HCC), thus mTOR and IGF1R represent suitable therapeutic targets in HCC. The aim 
of this study was to evaluate the effects of mTOR inhibitors (mTORi) and OSI-906, 
blocker of IGF1R/IR, on HCC cell proliferation, viability, migration and invasion, and 
alpha-fetoprotein (α-FP) secretion. In HepG2 and HuH-7 we evaluated, the expression 
of mTOR and IGF pathway components; the effects of Sirolimus, Everolimus, 
Temsirolimus and OSI-906 on cell proliferation; the effects of Sirolimus, OSI-906, 
and their combination, on cell secretion, proliferation, viability, cell cycle, apoptosis, 
invasion and migration. Moreover, intracellular mechanisms underlying these cell 
functions were evaluated in both cell lines. Our results show that HepG2 and HuH-
7 present with the same mRNA expression profile with high levels of IGF2. OSI-
906 inhibited cell proliferation at high concentration, while mTORi suppressed cell 
proliferation in a dose-time dependent manner in both cell lines. The co-treatment 
showed an additive inhibitory effect on cell proliferation and viability. This effect was 
not related to induction of apoptosis, but to G0/G1 phase block. Moreover, the co-
treatment prevented the Sirolimus-induced AKT activation as escape mechanism. Both 
agents demonstrated to be differently effective in inhibiting α-FP secretion. Sirolimus, 
OSI-906, and their combination, blocked cell migration and invasion in HuH-7. These 
findings indicate that, co-targeting of IGF1R/IR and mTOR pathways could be a novel 
therapeutic approach in the management of HCC, in order to maximize antitumoral 
effect and to prevent the early development of resistance mechanisms.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most 
common malignancy worldwide and the third most 
frequent cause of global cancer-related mortality [1, 2]. 
If diagnosed at early stage, HCC can be cured by surgical 
tumor resection or liver transplantation [2]. However, only 
10-20% of patients are candidates for curative surgery, 
and approximately 80-90% of patients are not eligible for 
surgery because of the extent of tumor, the tumor spread 
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and the level of underlying liver dysfunction [1–4]. 
HCC has been shown to be chemoresistant to the most 
common chemotherapic compounds [2]. In this setting, 
targeted therapies could represent a new therapeutic 
option in HCC patients. In particular, sorafenib, a small 
molecule multi-tyrosine kinase inhibitor, has been 
demonstrated to improve survival, in terms of median 
overall survival, in patients with advanced HCC [2, 5], 
although approximately one-third of patients treated with 
sorafenib experience disease progression [6]. Therefore, 
novel treatment options are required in the management 
of HCC.
Hepatocarcinogenesis has been suggested to be 
a complex multistep process characterized by a broad 
spectrum of molecular abnormalities [7]. The study of the 
molecular mechanisms involved in HCC pathogenesis has 
highlighted the existence of several signaling pathways, 
which might be targetable with new therapies, representing 
new potential treatments in patients with advanced HCC. 
Particularly, an increased expression of insulin-like growth 
factor (IGF) 2 and IGF1 receptor (IGF1R) [8–11] and a 
deregulation of the phosphatidylinositol 3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) pathways 
[7, 12] have been reported in HCCs.
The IGF signaling pathway is a controlled 
endocrine system that is physiologically involved in the 
regulation of human development, energy balance, cell 
growth and development and it is biologically active 
in many neoplastic processes [11]. IGF1R is a tyrosine 
kinase receptor sharing approximately 84% amino acid 
homology with insulin receptor (IR). IGF1R, activated 
by IGF1 and IGF2 derived from endocrine, autocrine 
and paracrine sources, transduces signals to PI3K/AKT/
mTOR and mitogen-activated protein kinase (MAPK) 
signaling pathways, via insulin receptor substrate 1 (IRS-
1), mediating the regulation of cell growth, proliferation, 
motility, invasion and metastasis, in a variety of human 
malignancies [13]. Therefore, the IGF pathway is 
considered a potential target for antineoplastic therapy in 
several tumors, including HCC [13, 14].
mTOR is a serine/threonine protein kinase that 
controls cell growth in response to nutrients and growth 
factors and it has been found to be frequently deregulated 
in cancer. mTOR resides in two distinct complexes named 
mTOR complex 1 (mTORC1) and 2 (mTORC2); both 
complexes are activated by distinct upstream signals, 
regulate different biological processes and have different 
sensitivities to rapamycin, a macrolide ester produced by 
Streptomyces hygroscopicus [15–17]. Activation of the 
PI3K by growth factors results in the phosphorylation 
of AKT which consequently elicits mTORC1 activation, 
leading to the downstream phosphorylation of two 
main effectors: eukaryotic translation initiation factor 
4E-binding protein 1 (4eBP1 (EIF4EBP1)) and ribosomal 
protein S6 kinase 1 (p70S6K (RPS6KB1)). Both 4eBP1 
and p70S6K are regulators of mRNA translation and 
stimulate the synthesis of several proteins involved in 
cell proliferation [18]. The use of rapamycin (Sirolimus) 
and its analogues (mTOR inhibitors (mTORi)) in 
preclinical and clinical investigations has revealed that 
mTORC1 pathway is involved in a network of signaling 
cross-talk and feedback mechanisms and that mTORC1 
inhibition results in loss of negative feedback loop and 
in the activation of AKT and MAPK pathway, reducing 
the effectiveness of mTORi in cancer treatment [19–21]. 
Therefore, a potential concomitant suppression of PI3K/
AKT/mTOR and MAPK pathways, targeting IGF1R/IR 
and mTOR, can be highly detrimental for tumor growth.
The aims of the current study were: 1) to 
characterize the IGF and mTOR pathways, 2) to evaluate 
the effect of IGF1R/IR blocking, using the dual inhibitor 
OSI-906, and mTOR blocking, using several mTORi as 
single agents and 3) to evaluate wheter the combination of 
the two categories of compounds has an additive effect in 
the regulation of cell secretion, proliferation, migration, 
invasion and cell cycle in two HCC cell lines.
RESULTS
mTOR and IGF pathway components are 
expressed in HCC cell lines and HCC tissues
In the attempt to define the role of mTOR and IGF 
pathways in HCC, RT-qPCR was performed to quantify 
the messenger expression level of mTOR, 4eBP1, 
p70S6K, IGF1, IGF2, IGF1R, IGF2R and IR (isoforms 
A and B), in THLE-2, HepG2 and HuH-7 cell lines, in 
normal liver and in HCC and peritumoral tissues. Both 
HCC cell lines presented the same messenger expression 
profile as shown in (Figure 1A and 1B). All mTOR and 
IGF pathway components were expressed in HCC tissues 
(Supplementary Figure S1 and Supplementary Figure S2) 
and in THLE-2, HepG2 and HuH7 cells (Figure 1A and 
1B) except IGF1 that was surprisingly not detectable in 
both HCC cell lines. The messenger levels of mTOR and 
IGF pathway components of cell lines were compared 
to the normal hepatocytes (THLE-2) and are reported 
in Supplementary Table S1 as mean±S.E.M. mTOR 
components and activated forms of IGF1R and IR were 
expressed at protein levels in HepG2 and HuH-7 cells as 
shown in (Figure 1C, 1D, 1E and 1F). In both HCC cell 
lines, mTOR was essentially located at perinuclear and 
cytoplasmic level, whereas, p70S6K and 4eBP1 were sited 
in the nucleus and in the cytoplasm. In both HCC cell lines, 
IR and IGF1R resulted to be activated in basal condition.
OSI-906 exerts a moderate antiproliferative 
effect in HCC cell lines
In both HCC cell lines, the treatment with OSI-
906 at serial concentrations between 10−10 and 10−6M did 
not induce a clear dose- and time-dependent inhibition 
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of proliferation. In both cell lines, the maximum effect 
was reached only at the maximum dose (10−6M) after 9 
days of treatment: (HepG2: 30% of inhibition, p<0.001; 
IC50>100nM); HuH-7: 24% of inhibition, p<0.001; 
IC50>100nM). Dose-time response curves for both 
cell lines are shown in (Figure 2A and 2B). The IC50 
and the inhibition of cell proliferation after 3, 6 and 
9 days of treatment in both cell lines are summarized 
in Supplementary Table S2. The value of inhibition is 
reported as percentage (p value vs control).
mTORi induce dose-dependent and 
time-dependent antiproliferative effect in 
HCC cell lines
SIR, EVE and TEM significantly suppressed 
cell proliferation in a dose- and time-dependent 
manner (Figures 2A and 2B). In HepG2 all the mTORi 
significantly inhibited cell proliferation after 3, 6 and 
9 days of treatment. In these cells, all the compounds 
showed the maximum effect after 9 days of treatment at 
the highest tested concentration (10−8M): the inhibitory 
effects of SIR, EVE and TEM were 93.16% (p<0.001), 
91.13% (p<0.001) and 91.28% (p<0.001), compared 
to the control, respectively. In HuH-7 all the mTORi 
were able to significantly inhibit cell proliferation 
after 3, 6 and 9 days of treatment. The maximum effect 
was reached after 9 days of treatment at the highest 
tested concentration (10−8M): the inhibitory effects of 
SIR, EVE and TEM were 95.9% (p<0.001), 83.32% 
(p<0.001) and 95.83% (p<0.001), compared to the 
control, respectively. The IC50 and the inhibition of cell 
proliferation after 3, 6 and 9 days of treatment in both 
cell lines are summarized in Supplementary Table S2. 
The value of inhibition is reported as percentage (p value 
vs control).
Combining Sirolimus and OSI-906 induces 
an additive inhibition of proliferation and cell 
viability in HCC cell lines
In order to show an enhancement strengthening of 
the antineoplastic effect of OSI-906 and SIR, cells were 
treated with 10−10M SIR and 10−6M OSI-906, as single 
agents and in combination (S+O). After 3, 6 and 9 days 
of treatment, SIR and OSI-906 significantly suppressed 
cell proliferation and the drug combination induced an 
additive inhibition of cell proliferation in both cell lines 
(Figure 3A and 3B). In HepG2, S+O induced a 94.43% 
of inhibition after 9 days (p<0.001 vs control, p<0.001 vs 
SIR and p<0.001 vs OSI-906) (Figure 3A) of treatment.In 
HuH-7, S+O induced a 92.64% of inhibition after 9 days 
(p<0.001 vs control, p<0.01 vs SIR and p<0.001 vs OSI-
906) (Figure 3B).
The combined treatment further inhibited HepG2 
cell viability compared to single agents showing an 
additive effect after 6 and 9 days of treatment (72.85% of 
inhibition: p<0.001 vs control, p<0.05 vs SIR and p<0.05 
vs OSI-906) (Figure 3C). The drug combination showed 
additive inhibition of HuH-7 cell viability after 3 and 6, 
with a maximum effect (70.29%) of inhibition after 9 days 
(p<0.001 vs control and p<0.001 vs OSI-906) (Figure 3D) 
Figure 1: A. and B. mRNA relative expression of components of the mTOR and IGF pathways. C. and D. protein expression of phospho-
IR and phospho-IGF1R in HepG2 and HuH-7 cells. E. and F. protein expression of mTOR components in HepG2 and HuH-7 cell lines. 
Black and white: contrast phase images. Blue: DAPI for nuclei staining. Green: FITC for p70S6K staining. Red: TRITC for mTOR and 
4eBP1 staining.
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in which the effect was not significant different from the 
effect of SIR.
Sirolimus and OSI-906 regulate cell cycle profiles 
in HCC cell lines
To determine the effects of OSI-906 and SIR on cell 
cycle progression, HepG2 and HuH-7 cells were treated 
with drugs alone and in combination and analyzed for cell 
cycle phase. As shown in Figure 4A, in HepG2, 24hrs 
of combined treatment with SIR and OSI-906 resulted 
in an increased rate of arrested cells in G0/G1 phase, 
compared to each compound alone (OSI-906 vs control 
p<0.05; S+O vs control p<0.01; S+O vs OSI-906 p<0.05; 
S+O vs SIR p<0.01) and, accordingly, in a decreased 
percentage of cells in the S phase (OSI-906 vs control 
p<0.05; S+O vs control p<0.01). In HuH-7, 24hrs single 
and combined treatment with SIR and OSI-906 did not 
induce a significant increased rate of arrested cells in G0/
G1 phase compared to the control. No increased rate of 
cells in subG1 phase was present in both cell lines treated 
with SIR and OSI-906, alone or in combination, indicating 
Figure 3: Antitumor effects of Sirolimus and OSI-906, alone and in combination, in both cell lines. Since both drugs were 
diluted in DMSO, a double amount of DMSO was added to the control wells and the cells treated with the single agents were supplemented 
with an extra amount of DMSO. Data are expressed as percentage of control and represent the mean ± S.E.M. of at least three independent 
experiments for each cell line. Control is set as 100%. *P<0.05; **P<0.01; ***P<0.001. Drugs effects on A. HepG2 cell proliferation and 
on C. HepG2 cell viability, on B. HuH-7 cell proliferation and on D. HuH-7 cell viability.
Figure 2: A. and B. Dose-time-dependent effect of the treatment with mTORi on cell proliferation, expressed as DNA content/well after 
3 days (closed circle, black), 6 days (closed square, gray), and 9 days (closed triangle, light gray) of treatment, in HepG2 and HuH-7. Data 
are expressed as percentage of control and represent the mean ± S.D. of three independent experiments. Control is set as 100%.
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the absence of apoptotic cells, as confirmed by the lack 
of Poly(ADP-ribose) polymerase (PARP) cleavage 
(Figure 4B).
Sirolimus and OSI-906 induce a reduction of 
α-FP secretion in HCC cell lines
To test the effect of both drugs on cell secretion, α-FP 
secretion levels were measured in cell culture medium by 
CLIA. SIR and OSI-906 induced a significant inhibition of 
α-FP secretion, normalized to the amount of DNA in each 
well, in HepG2 and HuH-7, suggesting a direct effect of 
the two drugs on α-FP secretion. In HepG2, SIR 10−10M 
and OSI-906 10−6M induced a significant inhibition of 
α-FP secretion after 3, 6 and 9 days of treatment (Figure 5). 
SIR caused the maximum effect after 9 days of treatment 
(75%, p<0.001 vs control), while the maximum effect of 
OSI-906 was reached after 6 days of treatment (42,4%, 
p<0.001 vs control). The OSI-906 effect was partially lost 
after 9 days of treatment. The co-treatment induced the 
87% of inhibition (p<0.001) after 6 days and this effect 
was still sustained after 9 days of treatment.
In HuH-7, SIR 10−10M induced the maximum inhibition 
after 6 days of treatment (82%, p<0.001 vs control) and this 
effect was maintained also after 9 days. OSI-906 10−6M 
inhibited α-FP secretion only after 9 days with a maximum 
inhibitory effect of 23% (p<0.001 vs control). The combined 
treatment reached the maximum inhibitory effect after 9 days 
(93%, p<0.001 vs control). Nevertheless, although this effect 
was greater than that obtained with the single treatments, 
it was not significantly different from the α-FP secretion 
inhibition induced by the single treatment with SIR (Figure 5).
Sirolimus and OSI-906 suppress migration and 
invasion in HuH-7 cell line
At the experimental condition tested, the extent of 
migration of untreated HepG2 cells was very low and 
neither OSI-906 nor SIR further suppressed HepG2 cell 
migration (Figure 6A). In HuH-7, SIR did not inhibit cell 
migration (Figure 6B), while OSI-906 (p<0.001 vs control) 
and drugs combination (p<0.001 vs control) significantly 
decreased HuH-7 cells migration. Interestingly, in HuH-
7, the combined treatment showed an inhibition of 53% 
compared to the control and an additive effect in driving 
the inhibition of cell migration compared to single 
agents (p<0.001 vs control, SIR and OSI-906). Matrigel 
invasion assay was performed to investigate cell invasion 
capability. At the experimental condition tested, HepG2 
did not show invasion competence (Supplementary Figure 
S3). In HuH-7, SIR and OSI-906 caused a remarkable 
decrement of cell invasion, corresponding to 60% and 
47%, respectively, (p<0.001 vs control for both drugs) 
while the combined treatment did not show additive 
inhibition compared to treatment with each compound as 
a single agent (Figure 6C).
Combination of Sirolimus and OSI-906 regulates 
AKT/mTOR/p70S6K and ERK pathways in 
HCC cell lines
To investigate whether the cytostatic effects of OSI-
906 and SIR were correlated with changes in intracellular 
components belonging to both mTOR and IGF pathways, 
AKT/mTOR/p70S6K and ERK signaling have been 
Figure 4: A. Analysis of cell cycle repartition by flow cytometry in both cell lines. Data are reported as mean ± S.E.M. of three independent 
experiments for each cell line. B. Effects of Sirolimus and OSI-906, alone and in combination, on PARP cleavage in HepG2 and HuH-7 
cell lines.
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investigated. Whole-cell extracts in the presence of 
SIR and OSI-906, as single agents and in combination, 
were analyzed by Western blot. In HepG2, SIR did not 
induce a significant decrement of serum-induced p70S6K 
phosphorylation (Ser389), nor changed ERK1/2 (p42/
p44) phosphorylation, but caused a significant induction 
Figure 6: A. and B. effects of Sirolimus and OSI-906, alone and in combination, on cell migration after 24hrs of treatment, in HepG2 
and HuH-7 cell lines. Data are reported as mean ± S.E.M. of three independent experiments for each cell line. Control is set as 100%. 
***P<0.001. C. Effects of Sirolimus and OSI-906, alone and in combination, on cell invasion after 24hrs of treatment in HuH-7 cell line. 
Since both drugs were diluted in DMSO, a double amount of DMSO was added to the control wells and the cells treated with the single 
agents were supplemented with an extra amount of DMSO. **P<0.01; ***P<0.001.
Figure 5: Antisecretive effects of Sirolimus and OSI-906, alone and in combination, after 3, 6 and 9 days of treatment in 
HepG2 and HuH-7 cell lines. α-FP levels are expressed as percentage of control and represent the mean ± S.E.M. of three independent 
experiments for each cell line. Control is set as 100%. **P<0.01; ***P<0.001.
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of AKT phosphorylation (Ser473) (p<0.01 vs control). 
When used alone, OSI-906 did not caused any changes 
in the p70S6K, ERK1/2 and AKT phosphorylation 
compared to control. When OSI-906 was combined 
with SIR, serum-induced p70S6K phosphorylation was 
markedly inhibited compared to control (p<0.05) and 
further reduced compared to the effects of each drug used 
alone. Moreover, the activation of AKT and ERK1/2 was 
prevented by the combined treatment (Figure 7).
In HuH-7, SIR induced a significant decrement 
of serum-induced p70S6K phosphorylation (Ser389) 
(p<0.05) but no changes were observed in AKT and 
ERK1/2 phosphorylation. The treatment with OSI-906 
induced a significant inhibition of p70S6K and AKT 
phosphorylation (p<0.01 vs control) but no change of 
serum-induced ERK1/2 phosphorylation. After combined 
treatment no additive effect on AKT and p70S6K 
dephosphorylation was reported, but the combination of 
both agents resulted in a stronger dephosphorylation of 
ERK1/2 (p<0.05 vs control) (Figure 7).
DISCUSSION
HCC represents a chemoresistant aggressive type of 
cancer with generally poor prognosis [2, 4, 22]. Sorafenib 
is the only systemic therapy that has been demonstrated 
to prolong median survival and the time to progression 
in patients with advanced HCC [2, 5]. However, the 
overall outcomes are far from being satisfactory, firstly 
because of the genetic heterogeneity of HCC that can 
cause primary resistance to sorafenib and secondly 
because long-term exposure to sorafenib often results in 
acquired resistance of tumor cells to drug with consequent 
disease progression [6]. Therefore, new therapeutic 
strategies for HCC are needed. More effective systemic 
treatment options may include the combination of agents 
with additive/synergistic activity against HCC. mTORi 
have been used in the treatment of various solid tumors 
[23–27]. Despite their outstanding preclinical antitumor 
activity, mTORi, used as monotherapy in the management 
of HCC, have not confirmed the anticipated efficacy [28, 
29]. This is probably related to the activation of feedback 
compensatory loops leading to tumor cell resistance 
like the up-regulation of IRS-1 protein levels and the 
induction of IRS-1 phosphorylation [19], the activation 
of both Akt phosphorylation via mTORC2 [30–32] and 
MAPK pathway via S6K/PI3K/Ras pathway [20]. These 
mechanisms may counteract the anticancer efficacy and 
may explain the variable response rates, demonstrated in 
different tumor types, when treated with mTORi.
In this study, it has been hypothesized that the 
combination of a dual blocker of IGF1R/IR, OSI-906, with 
the mTORi SIR, would potentiate the antitumor effects of 
SIR used as a single agent in HCC cells, because down-
regulating AKT and MAPK survival pathway upstream 
with OSI-906, the resistance to mTORi, induced by 
mechanisms of escape, can be overcome. Therefore, for 
the first time, the effects of treatments with an mTORi 
and OSI-906 in terms of cell proliferation, viability, 
secretion, migration and invasion have been analyzed in 
two of the most common used HCC cell lines. Firstly, the 
expression of mTOR and IGF pathway components has 
been investigated in two human HCC cell lines, in one 
normal hepatocytes cell line, and confirmed in normal 
liver tissue and in HCC tissues and related peritumoral 
tissues. Both cell lines expressed comparable messenger 
levels of mTOR components, with higher levels of 
4eBP1and mTOR, compared to normal hepatocytes, and a 
similar profile for IGF pathway components, with higher 
IGF2 and IRB compared to normal hepatocytes. The 
mTOR components and the activated forms of IGF1R and 
IR expression have been also confirmed at protein levels in 
the investigated HCC cell lines. According to the literature, 
and confirmed by our study, HepG2 and HuH-7 do not 
express IGF1, but they express IGF1R and high levels of 
IGF2 [8]. This latter could lead to autocrine stimulation 
Figure 7: Effects of Sirolimus and OSI-906, alone and in combination, on AKT, p70S6K and ERK signalings after 
30′ of treatment with drugs, in HepG2 and HuH-7 cell lines. The blot in the figure is representative of at least two independent 
experiments for each cell line. Graphs represent the mean of at least two independent experiments for each cell line. *P<0.05; **P<0.01.
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of growth and motility through IGF1R and/or IR [33–35], 
acting as an important driver for HCC cell growth. The 
messenger and protein expression of IR has also been 
investigated previously in these two cell lines [8, 36]. In 
particular, IR protein expression has been investigated by 
western blot and a qualitative evaluation of IR isoform 
expression was conducted by RT-PCR analysis [8, 36]. 
Here the expression of both IR isoforms was investigated 
by RT-qPCR and comparable messenger levels of IRA and 
IRB were found in HepG2 and in HuH-7.
The in vitro antiproliferative and antisecretory 
effects of the mTORi and of the dual IGF1R/IR blocker, 
OSI-906, were evaluated. All used mTORi were been 
tested for the first time for a long period (9 days). The 
mTORi treatment induced a significant inhibition of 
cell growth in vitro, in a dose-time dependent manner, 
in both cell lines. Conversely, OSI-906, after both 
short-term (3 days) and long-term (9 days) treatment, 
was much less effective than mTORi in inhibiting cell 
proliferation, demonstrating that blocking IGF1R and IR 
is not a sufficient condition to reduce cell proliferation. 
Nevertheless, in both cell lines, OSI-906 showed a 
modest antiproliferative effect at high concentration. 
These results are consistent with a previous published 
study [8], whose results demonstrated that IR and IGF2 
expression levels are positively correlated with sensitivity 
to OSI-906. The decision to continue the experiments by 
combining OSI-906 with SIR in particular, among all the 
mTORi, was based on several observations. First of all, 
SIR is the first mTOR allosteric inhibitor; EVE and TEM 
are synthetic rapamycin analog compounds, also known 
as “rapalogs”. Moreover, SIR and OSI-906 have shown 
antitumor activity, as single agents, in preclinical studies 
in HCC [8, 37–39]. Secondly, PI3K/AKT/mTOR and 
MAPK pathways are critical for cell proliferation, survival 
and resistance to apoptosis and both SIR and OSI-906 
interact with these pathways [8, 31], which are known to 
be deregulated in HCC. Therefore, we choose to combine 
SIR with OSI-906 at concentrations of 10−10 M and 10−6M 
respectively, taking into account that these concentrations 
are lower than the maximum concentration achieved in 
blood, in patients with solid tumors enrolled in Phase I/II 
clinical trials [40, 41].
The combined treatment with SIR and OSI-906 
showed an additive antiproliferative effect, in terms of 
both proliferation and viability, compared to treatment 
with both agents used alone. The analysis of the 
mechanisms underlying these antiproliferative effects 
revealed that in HepG2 the combined treatment with SIR 
and OSI-906 did non induce a significant inhibition of 
ERK1/2 phosphorylation compared with the control, but 
caused a significant block of the ERK1/2 phosphorylation 
triggered by the single treatment with SIR and OSI-
906. Moreover, the co-treatment significantly blocked 
the escape pathway mediated by AKT phosphorylation, 
which follows the inhibition of mTORC1. The inhibition 
of p70S6K activation induced by the co-treatment with 
SIR and OSI-906, was more pronounced than treatment 
with single agents, but not significantly different. In HuH-
7, the co-treatment did not induce a stronger inhibition 
of ERK1/2 and p70S6K phosphorylation, compared to 
treatment with single agents. SIR was not able to block the 
AKT phosphorylation. Nevertheless, OSI-906 abrogated 
the escape pathway on AKT, induced by the treatment with 
SIR. Although SIR has been previously reported to induce 
cell apoptosis [42], G0/G1 phase arrest, and not apoptosis, 
appeared the predominant mechanism responsible for the 
observed antiproliferative effects of SIR and OSI-906 in 
single and combined treatment. It could be speculated that 
the arrest in G0/G1 phase, mediated by these drugs, is due 
to the trigger of senescence [43] or autophagy [44].
The most widely used onco-glycoprotein marker 
for detecting HCC is serum α-FP [45]. It has been 
demonstrated that α-FP has pleiotropic effects, affecting 
the processes of cell differentiation, cell proliferation 
and tumorigenesis [46, 47]. The results of the current 
study demonstrated that both drugs induced a significant 
reduction of α-FP secretion after 3, 6 and 9 days of 
treatment in HepG2, while SIR has a pivotal role in 
inhibiting α-FP secretion compared with OSI-906 in HuH-
7, independently from the effect on cell proliferation. The 
mechanisms responsible for this effect still need to be 
clarified.
Cell migration and invasion are implicated in the 
pathophysiology of many diseases, including cancer 
[48]. Prior to and during metastatization, tumor cells 
undergo several morphological changes and acquire an 
increased motility potential. Cell migration and invasion 
are critical parameters in the formation of metastasis [48].
The inhibition of these two key-processes can block the 
metastatic process, based on neoplastic cells invasion into 
the surrounding tissue and intravasation into blood or 
lymphatic vessels [48]. In this study it was demonstrated 
for the first time that SIR and OSI-906 can arrest migration 
and invasion of HuH-7, and, furthermore, the combination 
of the two agents showed an additive inhibition of cell 
migration. HuH-7 is a selected HCC cell line with more 
mesenchymal characteristics compared to HepG2 cell 
line; indeed, it has been previously showed that HuH-7 
cells express mesenchymal markers (Vimentin and Zeb1) 
contrarily to HepG2 cells, which mainly express epithelial 
markers (E-cadherin and ErbB3) [8]. The epithelial pattern 
of expression showed by HepG2 could suggest that these 
cells behave more like epithelial than mesenchymal cells, 
thus providing an explanation for the lacking invasion 
capability of this cell line.
In conclusion, although the use of mTORi and OSI-
906 failed to provide beneficial clinical effects in HCC 
and other solid tumors when used as single agents, this 
in vitro study produces the evidences of a significant 
antitumor effect of the combined treatment with SIR and 
OSI-906 in human HCC cell lines. These results represent 
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the rationale for the interest in the co-targeting of IGF1R/
IR and mTOR pathways as a novel therapeutic approach 
in patients with HCC, in order to maximize the antitumor 
effect and to prevent the early development of resistance 
mechanisms.
MATERIALS AND METHODS
Study design
In this study, two HCC cell lines (HepG2 and HuH-
7), one normal hepatocyte cell line (THLE-2) and seven 
HCC and peritumoral tissues were characterized for the 
mRNA expression of the most important components 
of the IGF and mTOR pathways. Moreover, in HCC 
cell lines, protein expression of mTOR components 
and p-IGF1R and p-IR has been detected as well. The 
effects of mTORi (Sirolimus (SIR), Everolimus (EVE), 
Temsirolimus (TEM)) and the dual inhibitor of IGF1R 
and IR, OSI-906, as single agents, were tested in dose- 
and time (3, 6 and 9 days)-dependent manner on cell 
proliferation. The serial doses used for these experiments 
ranged between 10−14 and 10−8M and between 10−10 and 
10−6M for the mTORi and OSI-906, respectively. In order 
to explore the effects of mTORi in combination with OSI-
906 in both human HCC cell lines, selected doses of SIR 
(10−10M) and OSI-906 (10−6M) were tested as single agents 
and in combination (S+O) at different incubation times 
according with the different experimental procedures, 
in particular after 3, 6 and 9 days of treatment on cell 
proliferation, viability and secretion, and after 24 hours 
of treatment on migration, invasion and cell cycle. In the 
experiments using the combination of two drugs, SIR was 
chosen among the different mTORi since it is considered 
the reference mTORi compound, and the selected doses 
used for the combined treatment were chosen as doses 
lower than blood maximal concentration (Cmax) reached 
in the target population of the pharmacokinetic studies 
reporting the therapeutic response of these agents [49, 50]. 
The times used for the different experiments were selected 
based on the appropriate times for each experimental 
methodology. In order to analyze the signalling mechanism 
underling the investigated processes, in both cell lines 
the effect of SIR plus OSI-906 on mTOR and MAPK 
components (AKT, ERK1/2, p70S6K phosphorilation) and 
on Poly(ADP-ribose) polymerase (PARP) cleavage were 
evaluated.
Cell lines
THLE-2 cell line, derived from primary normal 
liver cells , was purchased from ATCC (American Type 
Culture Collection) and cultured in Williams E without 
fenol red with 10% FBS, 1 × 105 U/L penicillin and 
streptomycin, cell maintenance cocktail B (Gibco) and 
10mM Dexamethasone (Gibco). Two human HCC cell 
lines, HepG2 and HuH-7, were purchased from ECACC 
(European Collection of Cell Cultures) and Health Science 
Research Resources Bank (HSRRB), respectively. HepG2 
cells, whose doubling time is around 48h, were cultured 
in RPMI 1640 medium with 10% of FBS, 1 × 105 U/L 
penicillin and 2mmol/L L-glutamine, whereas HuH-
7, whose doubling time is around 31h, were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) GlutaMax 
medium with 10% of FBS and 1 × 105U/L penicillin and 
streptomycin. Cell lines were grown in a humidified 
condition in 5% CO2 at 37°C. HCC cell lines identity 
was confirmed by short tandem repeat profiling (LGC 
Standards Cell Line Authentication service).
HCC human tissues
Seven frozen tissues and their peritumoral 
biospecimens have been supplied by Biobank of Istituto 
Nazionale per lo Studio e la Cura dei Tumori “Fondazione 
Giovanni Pascale” (IRCCS) of Naples. For the use of the 
clinical materials for research purposes, the Institutional 
Research Ethics Committee approved the study, and prior 
patient consent was obtained.
Drugs and reagents
The mTORi, SIR, EVE and TEM, and the IGF1R/IR 
inhibitor, OSI-906, were purchased from LC Laboratories 
(Inc. Woburn, MA, USA). All compounds were dissolved 
in dimethylsulfoxide (DMSO) 100%, as recommended by 
the manufacturer, as stock solutions concentrated 10−3M 
and stored at −20°C. For each experiment, serial dilutions 
in DMSO 40% were freshly made prior to use.
RNA isolation and quantitative RT-PCR
RT-qPCR was performed to quantify the messenger 
expression level of the most important mTOR pathway 
components (mTOR, 4eBP1 and p70S6K) and of IGF 
pathway components (IGF1, IGF2, IGF1R, IGF2R, and 
IR (isoforms A and B)) in THLE-2, HepG2, HuH-7 cell 
lines and in HCC and peritumoral tissues. The cells and 
the tissues were lysed on ice in a lysis binding buffer 
containing 100 mM Tris-HCl (pH 8.0), 500 mM LiCl, 
10 mM EDTA (pH 8.0), 1% LiDS, 5 mM DTT, and 5 
U/100 μl ribonuclease inhibitor (HT Biotechnology 
Ltd., Cambridge, UK). The mRNA was isolated from 
total RNA with the use of prewashed Dynabeads Oligo 
(dT)25 (Dynal AS, Oslo, Norway) for 10′ on ice. The 
beads were collected with a magnet and washed three 
times with 10 mM Tris HCl (pH 8.0), 0.15 M LiCl, 1 
mM EDTA, 0.1% LiDS, and once with a similar buffer 
from which LiDS was omitted. The poly (A+) mRNA 
was eluted twice, for 2′ each time, in H2O (65°C) and 
20 μl were used for cDNA synthesis in a Tris buffer (50 
mM Tris–HCl (pH 8.3), 100 mM KCl, 4 mM DTT and 
10 mM MgCl2) with 10 units RNase inhibitor, 2 units 
avian myeloblastosis virus Super Reverse Transcriptase, 
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oligo dT (5 ng/μl) and 1 mM of each dNTPs in a final 
volume of 40 μl. This mix was incubated for 1 h at 42°C 
and the resulting cDNA was diluted fivefold in 160 μl 
sterile H2O. The cDNA was used for quantification of 
mRNA levels of all investigated genes. The total reaction 
volume (12.5 μl) consisted of 5 μl of cDNA and 7 μl of 
TaqMan Universal PCR Mastermix (Applied Biosystems, 
Branchburg, NJ, USA) with primers-probes. Primers 
and probes sequences and concentrations are shown in 
Supplementary Table S3. All primers and probes were 
purchased from Sigma-Aldrich. RT-qPCR was performed 
in 96-well optical plates with the TaqMan Gold nuclease 
assay (Perkin Elmer Corporation, Foster City, CA, USA) 
and the ABI Prism 7900 Sequence Detection System 
(Perkin Elmer, Groningen, The Netherlands), using the 
standard protocol. Briefly: after two initial heating steps 
at 50°C (2′) and 95°C (10′), samples were subjected to 40 
cycles of denaturation at 95°C (15”) and annealing at 60°C 
(60”). All samples were assayed in duplicate. Values were 
normalized against the expression of the housekeeping 
gene phosphoribosyltransferase (HPRT). Results are 
expressed as mean of three different experiments. Dilution 
curves were constructed to calculate PCR efficiencies (E) 
for every primer–probe set [51]. Primer’s efficiencies have 
been reported in Supplementary Table S3. The relative 
expression of target genes was calculated using the 
comparative threshold method, 2−ΔCt [52] with efficiency 
correction of target and reference gene transcripts, as 
described previously [53]. To exclude genomic DNA 
contamination in RNA extracts, cDNA reactions were also 
performed without reverse transcriptase and amplified with 
each primer pair. To exclude contamination of the PCR 
mixtures, reactions were also performed in the absence of 
cDNA template, in parallel with cDNA samples.
Immunofluorescence staining
The cells were fixed in 4% paraformaldehyde/1X 
PBS for 30 min at 4°C into culture-slides. Slides 
were washed thrice in 1X PBS for 5 min and placed in 
permeabilization buffer (Triton 0.25%/1X PBS) for 10 
min. After subsequent thrice washing in 1X PBS for 
5 min, slides were placed in blocking buffer (5% goat 
serum/Triton 0.1%/1X PBS) for 1h at RT. The cells were 
incubated with primary antibodies against mTOR (rabbit 
monoclonal Ab, clone 7C10, #2983 Cell Signalling, 
diluted 1:200), p70S6K (mouse monoclonal Ab, clone 
H-9, sc-8418 Santa Cruz, diluted 1:50), 4eBP1(rabbit 
monoclonal Ab, #9644 clone 53H11, Cell Signalling, 
diluted 1:200) in blocking buffer for 1h at RT. Slides 
were washed thrice in 0.1% Triton/PBS for 5 min and 
incubated 1h with rhodamine-conjugated secondary 
antibodies (ImmunoReagents, Inc., Raleigh, NC) diluted 
1:1000 in blocking buffer for mTOR and 4eBP1 and with 
Fluorescein isothiocyanate (FITC)-conjugated secondary 
antibodies (Millipore, Temecula, California) diluited 
1:1000 for p70S6K. A 4.6-Diamidino-2-phenylindole 
(DAPI) (Lonza Group Ltd, Basel, Switzerland) staining, 
diluted in PBS 1X 1:40000, was used to visualize the 
nuclei. Negative controls were performed, in which 
cells were incubated with secondary antibody with the 
omission of the primary antibody. Staining was visualized 
on an inverted microscope Olympus IX51 equipped for 
fluorescence and phase contrast microscopy (Olympus, 
Milan, Italy) and the images were captured at 40X 
magnification and acquired with Olimpus Digital Camera 
F-View II (Olympus, Milan, Italy).
Phospho-receptor tyrosine kinase (RTK) array
Phospho-IGF1R and phosphor-IR were measured 
with Human Phospho-RTK Array Kit (#ARY001B) from 
R&D. HepG2 and HuH-7 cells were lysed and assays were 
carried out according to manufacturer’s protocols.
Cell proliferation assay
After trypsinization, HepG2 and HuH-7 cells were 
plated in 1 ml of complete culture medium in 24-well 
plates at different density, based on growth curves at 3, 
6 and 9 days. For HepG2, 3.5 × 104, 2.0 × 104 and 5 × 
103 cells were plated for 3, 6 and 9 days, respectively. 
For HuH-7-1, 3.0 × 104, 1.5 × 104 and 5 × 103 cells were 
plated for 3, 6 and 9 days, respectively. The plates were 
then placed in incubator in 5% CO2 at 37°C. After 24hrs, 
the test compounds were added to each well at different 
concentrations: SIR and TEM in a concentration range 
between 10−13 and 10−8M, EVE, that has been shown to 
be more effective than other mTORi in both cell lines, 
in a concentration range between 10−14 and 10−8M and 
OSI-906 in a concentration range between 10−10 and 
10−6M. Controls were vehicle-treated. Plates were further 
incubated at 37°C and 5% CO2. In experiments with 6 and 
9 days of treatment, medium was changed and compounds 
were fresly added every 3 days. After 3, 6 and 9 days of 
treatment, cells were harvested for DNA measurement. 
Also the combined effect of SIR (10−10M) and OSI-906 
(10−6M) was evaluated after 3, 6 and 9 days of treatment. 
Measurement of total DNA content, representative for the 
number of cells, was performed using the bisbenzimide 
fluorescent dye (Hoechst 33258) (Boehring Diagnostics, 
La Jolla, CA), as previously described [54].
Cell viability assay
After trypsinization, HepG2 and HuH7 cells were 
seeded in 96-well plates. Cells were plated in 100μL of 
culture medium at different density selected on the bases 
of previously performed growth curves at 3, 6 and 9 days. 
Particularly, 3 × 103, 2 × 103 and 1 × 103 HepG2cells were 
plated for 3, 6 and 9 days, respectively. 2.5 × 103, 1.5 × 
103 and 1 × 103 HuH-7cells were plated for 3, 6 and 9 days 
respectively. Cells were exposed to a single and combined 
treatment with SIR (10−10M) and OSI-906 (10−6M). 10μl of 
Oncotarget9728www.impactjournals.com/oncotarget
MTT solution, concentrated 5 mg/ml in PBS, was added 
to 90 μl of medium in each well. The cells were then 
cultured for a further 1h. MTT was removed and 100 μL/
well of solvent (isopropyl alcohol, 10% HCl) were added 
to the cells in constant stir for 15′ at room temperature. 
Absorbance was measured at 570 nm using a plate reader 
(Victor X4, Perkin Elmer, Italy). Vehicle-treated cells were 
used as control.
Flow cytometry analysis of cell cycle
HepG2 and HuH-7 were plated at density of 1,5 × 
105 in 6-well plates in full medium. Cells were allowed 
to fully adhere for 24hrs, then, SIR (10−10M) and OSI-
906 (10−6M) were added alone and/or in combination. 
Since both drugs were diluted in DMSO, a double amount 
of DMSO was added to the control wells and the cells 
treated with the single agents were supplemented with an 
extra amount of DMSO. After 24hrs of treatment, cells 
were harvested by trypsinization, washed with cold PBS, 
resuspended in PBS + EDTA, fixed in 96% ethanol and 
stored at -20°C overnight until the flow-cytometric assay 
was performed. Fixed cells were rinsed twice with PBS 
lacking calcium and magnesium and stained with 50μg/
mL of propidium iodide (PI) (Sigma Aldrich) in the 
presence of Rnase A (10μg/mL) at room temperature in the 
dark for 1h. DNA content was determined by FACSCanto 
II flow cytometer (Becton Dickinson, San Jose, CA), with 
a 488nm Coherent laser. The channel FL2 was used to 
analyse 20,000 events. Data were acquired by FACSDiva 
software (Becton Dickinson, San Jose, CA) and analysis 
was performed by using Modfit version 2.0 software.
Alpha-fetoprotein (α-FP) secretion
HepG2 and HuH-7 cells were cultured in 24-
well plates and treated for 3, 6 and 9 days as previously 
described for cell proliferation. The amount of α-FP in 
the cell culture supernatant was analyzed by immuno-
chemiluminescent assay (CLIA) (Liaison®, Diasorin, 
Torino, Italia).
Cell migration analysis
The in vitro scratch-wound healing assay was 
used to study cell migration [55]. HepG2 and HuH-7 
cells were seeded in poly-L-lysine pre-coated 12-well 
plates and were grown until 100% confluence. At this 
point, cells were exposed to 10−10M of SIR, 10−6M of 
OSI-906, and a combination of them, in culture medium 
containing a lower percentage of serum (1%), sufficient 
to prevent apoptosis or cell detachment and to minimize 
cell proliferation. After exposure, linear scratch-wounds 
were made in the cell monolayer using a p200 tip. 
Scratch wounds were then visualised using an inverted 
microscope, Zeiss Axiovert 40c, and pictures were 
captured by a digital camera, Canon power shot A640, at 
different time points: 0, 2hrs, 4hrs, 6hrs, 8hrs, and 24hrs. 
The areas of the scratch-wounds were analysed by Image 
J software (http://rsbweb.nih.gov/ij/). The rate of scratch 
closure was calculated by subtracting the remaining width 
of the scratch lines from the width of the baseline scratch 
(control) at consecutive time points. Each experiment was 
repeated at least three times. Four readings were made for 
each sample at each time point.
Transwell invasion assay
Cell invasion was assessed using BioCoat Matrigel 
Invasion Chambers (BD) [56]. Matrigel Invasion 
Chambers were hydrated in the tissue culture incubator 
for 2hrs, by placing serum free medium on the bottom of 
the well and in the top of the chamber. After hydration 
of the Matrigel, the medium in the bottom of the well 
was replaced with 800 μl of medium containing 10% 
FBS. 5 × 104 HepG2 and HuH-7 cells were plated in 200 
μl of serum free medium in the top of the chamber and 
were exposed to 10−10M of SIR, 10−6M of OSI-906, and 
a combination of them. The invasion assay was carried 
out for 24hrs in the tissue culture incubator. Cells were 
fixed by replacing the culture medium on the bottom and 
top of the chamber with 3,7% formaldehyde dissolved 
in PBS for 15′ at room temperature and with methanol 
for 2′. After fixing the cells, the chambers were rinsed in 
PBS and stained with Giemsa for 10′. After washing the 
chambers several times by dipping the chambers in a large 
beaker filled with PBS, the cells (now blue in color) on 
top of the Matrigel membrane were removed with several 
Q-tips. All the cells that remained in the chamber were 
the ones that invaded the membrane, passed throughout 
the membrane, and ultimately reached the bottom side of 
the membrane. Invasiveness was determined by counting 
cells in five microscopic fields per well, using an inverted 
microscope equipped with 10X objective. The rate of 
inhibition (%) was calculated using the following formula: 
(1 – number of invading cells of the treatment group/
number of invading cells of control group) × 100.
Protein extraction and western blot analysis
HepG2 and HuH-7 cell lines were plated into culture 
dishes and grown to 70-80% confluence. After drug 
treatment (30′) of FBS-stimulated cells, cells were lysed in 
detergent buffer (1% NP-40, 10% Glycerol, 137mM NaCl, 
20mM Tris pH7.6, 20mM NaF, 2μg/mL aprotinin, 2μg/
mL leupeptin, 2μg/mL pepstatin, 200μM Na3VO4, 1mM 
PMSF) on ice for 30′. The homogenate was centrifuged for 
15′, at 1200 x g and 4°C and the supernatant was collected 
and stored at -80°C until use. Protein concentrations 
were determined photometrically with a bicinchoninic 
acid (BCA) Protein Assay Kit (Thermo Scientific, USA). 
After protein heat-denaturation at 95°C for 10′, 40μg of 
total extracts were used for immunoblotting. Proteins 
from cell preparations were separated by 8% (according 
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to protein’s Molecular Weight detected) SDS-PAGE and 
then electroblotted onto a nitrocellulose membrane for 
1h in a TransBlot Amersham apparatus. After a blocking 
treatment for 1h with 5% of milk, the nitrocellulose filters 
were probed with primary antibodies specific for ERK1/2 
(sc-7383 Santa Cruz, Italy), ERK2 (sc-1647 Santa Cruz, 
Italy), pAKT (Ser 473) (#9271, Cell signalling, Italy), 
AKT (#9272, Cell signalling, Italy), pp70S6k (#9206,Cell 
signalling, Italy), p70S6k (sc-8418, Santa Cruz, Italy), 
PARP (#9542,Cell signalling, Italy) and β-actin (A4700; 
Sigma Aldrich, Italy) overnight; subsequently, filters 
were hybridated with peroxidise-conjugated secondary 
antibodies and immunoreactive bands were detected by 
ECL system. After chemiluminescent reaction, the blot 
was exposed to ImageQuant Las 4000 (GE Healthcare). 
The chemiluminescent signals of the appropriately sized 
bands were measured using the ImageQuant Las 4000 
image system software.
Statistical analysis
All the experiments were performed in 
quadruplicates and were replicated three times with the 
exception of western blot analysis that were replicated two 
times. All statistical analyses were performed using SPSS 
and GraphPad softwares. Non-linear regression (curve fit) 
analysis was used to identify the half-maximal inhibitory 
concentrations (IC50) for all used drugs. Differences 
between the treated groups were assessed by ANOVA, 
followed by a multiple comparative test (Newman-Keuls 
or Dunnett’s correction).
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